ArticleFrontiers in surgery2025
Feasibility and outcomes of robot-assisted partial splenectomy for benign splenic lesions: a single-center experience.
Article in Frontiers in surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To evaluate the feasibility, safety, and short-term clinical outcomes of robot-assisted partial splenectomy (RAPS) in the treatment of benign splenic lesions (BSLs). Methods: A retrospective analysis was conducted on nine patients with BSLs who underwent RAPS in the Department of Hepatobiliary, Pancreatic, and Splenic Surgery at Mianyang Central Hospital between January 2024 and September 2025. Clinical data, including demographic characteristics, lesion features, intraoperative parameters, postoperative recovery, and complications, were collected. All patients underwent preoperative contrast-enhanced abdominal computed tomography, magnetic resonance imaging, and three-dimensional (3D) reconstruction to delineate the anatomical relationship between the lesion and splenic vasculature. All procedures were performed by the same surgical team. Results: All nine procedures were successfully completed without conversion to open surgery. The cohort comprised three men and six women, with a mean age of 49.0 ± 10.3 years. Lesions were located in the lower pole in seven cases and in the upper pole in two, with a mean diameter of 4.34 ± 0.8 cm. The mean operative time was 179.4 ± 15.5 min, the mean intraoperative blood loss was 71.1 ± 19.6 mL, and the mean postoperative hospital stay was 6.4 ± 0.9 days. No cases of splenic infarction, pancreatic fistula, hemorrhage, or severe infection were observed. Pathological diagnoses included splenic hemangioma ( Conclusion: RAPS is a safe, feasible, and minimally invasive spleen-preserving procedure. Preoperative 3D reconstruction facilitates precise surgical planning, and when combined with the high-precision maneuverability of robotic technology, enables complete lesion removal while preserving functional splenic tissue. This approach aligns with the principles of modern precision and minimally invasive surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.